Braveheart Bio, Inc. Common Stock (BRVE)

• 1 day: 0.67%
• 5 days: -0.66%
• 1 month: 0.67%
• 3 months: 0.67%
• 6 months: 0.67%
• Year to date: 0.67%
• 1 year: 0.67%
• 5 years: 0.67%
• 10 years: 0.67%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).